- WuXi Biologics and Earendil Labs signed a strategic collaboration for developing bispecific/multispecific antibodies and ADCs.
- WuXi Biologics will provide end-to-end biologics development and manufacturing services.
- By 2025, WuXi Biologics had 945 projects on its CRDMO platform, with a focus on bispecific and multispecific antibodies.
- Earendil Labs uses AI-driven protein-engineering to advance its pipeline for autoimmune diseases and cancer.
Collaboration Overview
WuXi Biologics and Earendil Labs have entered a strategic collaboration to develop and manufacture bispecific and multispecific antibodies and ADC candidates. This partnership targets autoimmune diseases, cancer, and other conditions.
WuXi Biologics' Role
WuXi Biologics will provide comprehensive biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing. The goal is to accelerate regulatory timelines and support scalable global clinical development.
Technological Strengths
WuXi Biologics has a strong track record in complex biologics, with 945 projects on its CRDMO platform by 2025. The company leverages advanced technology platforms like WuXia™ TrueSite and WuXiHigh™ to enhance efficiency and product consistency.
Earendil Labs' Contribution
Earendil Labs brings AI-driven protein-engineering capabilities to the collaboration, aiming to advance its pipeline with speed and precision. The partnership is expected to integrate these capabilities with WuXi Biologics' expertise to achieve clinical milestones efficiently.
